| Identification | Back Directory | [Name]
Ertugliflozin | [CAS]
1210344-83-4 | [Synonyms]
PF-04971729 L-pyroglutamic acid
Ertugliflozin L-pyroglutamic Acid (1:1) | [Molecular Formula]
C27H32ClNO10 | [MDL Number]
MFCD27956909 | [MOL File]
1210344-83-4.mol | [Molecular Weight]
565.997 |
| Chemical Properties | Back Directory | [storage temp. ]
Inert atmosphere,2-8°C | [solubility ]
DMSO: ≥ 125 mg/mL (220.85 mM) | [form ]
Solid | [color ]
White to off-white | [InChIKey]
YHIUPZFKHZTLSH-NCRAORDPNA-N | [SMILES]
C([C@@H]1CCC(=O)N1)(=O)O.O[C@@H]1[C@H]([C@H](O)[C@]2(CO)CO[C@@]1(C1C=CC(Cl)=C(CC3C=CC(OCC)=CC=3)C=1)O2)O |&1:1,10,11,12,14,19,r| |
| Hazard Information | Back Directory | [Description]
Ertugliflozin L-pyroglutamic acid is a potent, selective, orally active sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor with an IC50 value of 0.877 nM for h-SGLT2.It is the main active ingredient in the tablet ertugliflozin. It is the main active ingredient of ertugliflozin tablets. It is used as an adjunctive therapy for type 2 diabetes. | [Chemical Properties]
Ertugliflozin L-pyroglutamic acid is a white to off-white powder, soluble in ethanol and acetone, slightly soluble in ethyl acetate and acetonitrile, and very slightly soluble in water. | [Uses]
Ertugliflozin L-pyroglutamic Acid is a reagent in the synthesis of Ertugliflozin (1210344-57-2) a sodium/glucose cotransporter 2 (SGLT2) inhibitor used to treat type 2 diabetes. | [Brand name]
STEGLATRO | [in vivo]
Ertugliflozin L-pyroglutamic acid (PF-04971729 L-pyroglutamic acid) reveals a concentration-dependent glucosuria after oral administration to rats[3]. | [IC 50]
SGLT2 |
|
| Company Name: |
DoEasy Pharma Co., Ltd. Gold
|
| Telephone: |
0571-0571-28806358 15397199029 |
| Website: |
http://www.deasypharma.com |
| Company Name: |
Valiant Co., Ltd.
|
| Telephone: |
0535-6101880 |
| Website: |
http://www.valiant-cn.com/ |
|